The authors demonstrated that treatment with artemisinin stimulated the phosphorylation of ERK1/2 and subsequent activation of the MAPK/ERK signaling pathway, which eventuated in memory improvement and reduction of apoptosis in this model of AD. Here, MAPK1 is linked to Alzheimer disease.